preprint · Research Square
Abstract Background The genetic complexity of Plasmodium falciparum is a contributory factor to the emergence of drug-resistant parasites. The WHO recommends intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) in malaria endemic settings. This study evaluated the prevalence of the Plasmodium falciparum multidrug resistance-1 gene ( mdr -1), genetic diversity of merozoite surface proteins ( msp-1 , msp -2) and glutamate-rich protein ( glurp ) among pregnant women from southwest Nigeria. Methods One hundred PCR-confirmed Plasmodium falciparum isolates, comprising visit 1 (V1) (n = 52), delivery (n = 31) and cord blood (n = 17), were randomly selected for analysis. The mdr -1 haplotypes were evaluated using restriction fragment length polymorphism (RLFP), while the msp-1 , msp-2 and glurp genes were genotyped using nested PCR. Allelic frequencies, proportions and multiplicity of infection were calculated, and the p value was considered ≤ 0.05. Results The mdr-1 (N86/N86Y) combination was detected in 11.8% (V1), 61.3% (delivery) and 58.8% (cord blood) from the isolates (p ≤ 0.05). The mutant (N86Y) haplotype was detected only in cord isolates (5.9%). The allelic frequency distribution for msp-1 was 245 (K1 = 81, MAD20 = 85 and RO33 = 79), and that for msp-2 was 110, representing 43.6% (FC27) and 56.4% (3D7), respectively. While glurp expressed the least allelic frequency of 25, 84% (V1), 12% (delivery) and 4% (cord), respectively (p ≤ 0.05). msp-1 and msp-2 recorded higher MOIs than glurp . Conclusion Antigenic falciparum strains with N86Y Pfmdr-1 , msp-1 , msp-2 , and glurp may compromise the effectiveness of IPTp-SP in southwest Nigeria. The search for newer drug formulations for IPTp may be needed.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21203/rs.3.rs-3726650/v1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.